Infinium Pharmachem Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Infinium Pharmachem Ltd is ₹ 210.2 as of 05 May 15:30 . The p/e ratio of Infinium Pharmachem Ltd changed from 28.2 to 46.3 over 2 quarters. This represents a CAGR of 169.57% The p/e ratio of Sanofi India Ltd changed from 30.8 to 0 over 7 quarters. This represents a CAGR of -100.00% The market cap of Infinium Pharmachem Ltd changed from ₹ 318.68 crore to ₹ 376.96 crore over 2 quarters. This represents a CAGR of 39.92% The market cap of Sanofi India Ltd changed from ₹ 18578 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The Revenue of Infinium Pharmachem Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Infinium Pharmachem Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Infinium Pharmachem Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Infinium Pharmachem Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Infinium Pharmachem Ltd

Infinium Pharmachem Limited was originally incorporated as 'Infinium Pharmachem Private Limited' on November 21, 2003 issued by the Registrar of Companies, Gujarat.
Later on, Company converted its status into Public Company and the name of Company was changed to 'Infinium Pharmachem Limited' vide fresh Certificate of Incorporation dated August 12, 2022.
Company is engaged in manufacturing and selling of Iodian based Pharmaceutical Intermediates.
The Company has its manufacturing plant at Dist.
Anand, Gujarat, since inception. The Company's manufacturing capabilities and technical expertise have catered industries such as Pharmaceutical & Biotech, Specialty & Performance Chemicals, Agrochemicals, Human Health, Animal Health, Cosmetics, Sanitation, Electrical, Electronics, etc.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Infinium Pharmachem Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Infinium Pharmachem Ltd or Sanofi India Ltd?

Market cap of Infinium Pharmachem Ltd is 327 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Infinium Pharmachem Ltd and Sanofi India Ltd?

The stock performance of Infinium Pharmachem Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Infinium Pharmachem Ltd and Sanofi India Ltd?

As of May 5, 2026, the Infinium Pharmachem Ltd stock price is INR ₹210.2. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Infinium Pharmachem Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Infinium Pharmachem Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.